Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright
The Fly

Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Entrada Therapeutics (TRDA) to $20 from $18 and keeps a Buy rating on the shares following the Q3 report. The company has two candidates approaching mid-stage clinical trial entry, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App